Press Releases

VETIGEL syringe

Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries

NEW YORK, Sept. 27, 2022 — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has entered into a Cooperative Research and Development Agreement (“CRADA”) with Walter Reed Army Institute of Research (“WRAIR”), the largest biomedical research facility administered by the U.S. Department of Defense (“DoD”), to advance the development of medical …

Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries Read More »

CHG Cresilon Hemostatic Gel Logo

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology

NEW YORK — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced today it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for its proprietary hemostatic gel technology. This follows Cresilon’s successful launch of VETIGEL®, its revolutionary hemostatic gel for the animal health market. …

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology Read More »

Cresilon's GMP manufacturing facility in Brooklyn, NY

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel

NEW YORK, April 8, 2021 – Cresilon, Inc., the Brooklyn-based biotechnology company, announced today the successful close of its Series A-3 financing, totaling $38.5 million. This financing is expected to allow the company to aggressively accelerate its global growth plan and expand the rollout of VETIGEL®, its revolutionary hemostatic gel for the animal health market. It …

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel Read More »